voxelotor,gbt021601
global blood therapeutics
[]
gbt presents positive new real-world evidence data at eha2022 congress further supporting clinical use of oxbryta (voxelotor) in sickle cell disease - results from phase 1 study of gbt601, including incremental new data, support advancing into planned ... 
CEO Of Digital Media Online